At Enclear Therapies, our mission is to improve and extend the lives of genetically defined populations of patients suffering from neurodegenerative disease through the advancement of biomedical science and engineering to develop controlled access, delivery, and modification of cerebrospinal fluid.
Targeting toxic proteins in CSF
Enclear Therapies is developing device-based systems to halt the progression of neurodegenerative diseases by removing toxic proteins known to drive pathology. The system 1. continuously recirculates cerebrospinal fluids (CSF) and 2. targets and removes toxic proteins from CSF.
President & CEO, Co-Founder
Anthony R. DePasqua
20yrs Med Tech Experience
Business & Product Dev, Marketing & Sales, Portfolio Strategy
Developed & Launched Platform Tech, Disposables & Services
Neuro, Ortho & Oncology
EnClear Therapies, Inc.
65 Parker Street #3A. Newburyport, MA 01950